Global Hyperkalemia Drugs (Acute & Chronic) Market 2019-2023 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 9, 2019--The “Global Hyperkalemia Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The hyperkalemia drugs market will grow at a CAGR of more than 20% during the forecast period.
The growing cases of various chronic diseases such as chronic kidney diseases and cardiovascular-related disorders are driving the market growth. Chronic kidney diseases increase the risk of patient developing hyperkalemia significantly, as the kidneys lose the ability to excrete potassium through urine. The ability of kidneys to excrete potassium decreases with time, which increases the risk of hyperkalemia becoming acute. Similarly, cardiovascular-related disorders also increase the risk of hyperkalemiain people. Hence, the increasing prevalence of these diseases is expected to contribute heavily of the growth of the market during the forecast.
Increasing prevalence of hyperkalemia
The global hyperkalemia drugs market has witnessed a growth in recent years, primarily due to the increasing prevalence of the disease globally. The recurring nature of the disease is another factor that is expected to contribute to the huge unmet need globally. Due to the increasing prevalence and the huge unmet need, the market has witnessed the approval of novel drugs.
Lack of approved therapies
The treatment using these therapies is known to decrease the potassium levels in the blood only to a certain extent. Due to the presence of a limited number of approved therapies, the market has huge growth potential; however the pipeline for hyperkalemia is weak, with only two molecules bring studied currently. These molecules are in the pre-clinical stages of development and are not expected to enter the market during the forecast period.
The global hyperkalemia drugs market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 04: MARKET SIZINGMarket sizing 2018 Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition
PART 06: MARKET SEGMENTATION BY TYPEComparison by type Chronic hyperkalemia Acute hyperkalemia Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPEGeographic segmentation Geographic comparison Key leading countries Market opportunity
PART 09: DRIVERS AND CHALLENGES
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPELandscape disruption Competitive scenario
PART 12: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors Ardelyx AstraZeneca Perrigo Sanofi Vifor Pharma
For more information about this report visit https://www.researchandmarkets.com/research/tkdb6m/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190109005458/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Liver and Kidney Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/09/2019 08:29 AM/DISC: 01/09/2019 08:29 AM